Personalized mRNA Immunotherapies Launching in the UK

BioNTech SE today announced that it signed a Memorandum of Understanding ("MoU") with the Government of the United Kingdom ("UK") focused on personalized mRNA immunotherapies.

The MoU aims to provide personalized cancer therapies for up to 10,000 patients by the end of 2030.

This objective is part of a multi-year collaboration focused on three strategic pillars: cancer immunotherapies based on mRNA or other drug classes, infectious disease vaccines, and investments into expanding BioNTech's footprint in the UK as one of the Company's key markets.

The next steps of the collaboration will be the selection of candidates, trial sites, and the set-up of a development plan to be ready to enroll the first cancer patient in the second half of 2023.

Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech, commented in a press release on January 6, 2023, "Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years."

"The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide."

BioNTech stated it plans to invest in a UK Research and Development ("R&D") hub in Cambridge with an expected capacity of more than 70 highly skilled scientists, the first to commence R&D by the end of the first quarter of 2023. 

Disclosure: Content was manually curated for mobile readers.